Skip to main content
Premium Trial:

Request an Annual Quote

Ambion Inks Deal With Applied Biosystems to Combine RNAi, PCR Reagents

NEW YORK, Jan. 19 (GenomeWeb News) - Ambion said today that it has struck a deal to combine its siRNA products with Applied Biosystems' real-time PCR reagents.


Under the deal, Ambion and Applied Biosystems will co-market the resultant products for conducting and monitoring RNAi-based mammalian gene knockdown. Ambion said it will also use Applied Biosystems' TaqMan Assays-on-Demand gene expression products to validate its siRNA products.


Additional terms of the deal were not disclosed.